Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA

A routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Formulations Facility of Strides Pharma Inc. USA (SPI), a step-down wholly owned subsidiary of Strides Pharma Science Limited, at Chestnut Ridge, New York, USA during the period December 17, 2025 to December 23, 2025.

At the conclusion of the inspection, the U.S. FDA has issued a Form 483 with four observations. These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products. SPI will respond to these observations comprehensively to FDA within the stipulated time and is confident of addressing all the observations to the satisfaction of USFDA.

Shares of Strides Pharma Science Limited was last trading in BSE at Rs. 938.40 as compared to the previous close of Rs. 969.90. The total number of shares traded during the day was 8673 in over 464 trades.

The stock hit an intraday high of Rs. 974.95 and intraday low of 932.50. The net turnover during the day was Rs. 8211409.00.

Source : Equity Bulls

Keywords

StridesPharmaScience INE939A01011 Pharmaceuticals cGMPInspection Form483 USFDA 4Observations